These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 15551509)

  • 1. From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.
    Hung JC;
    J Nucl Med; 2004 Oct; 45(10):13N, 16N. PubMed ID: 15551509
    [No Abstract]   [Full Text] [Related]  

  • 2. Exemption of radiopharmaceuticals from <797>.
    Hung JC; VanBrocklin HF
    J Nucl Med; 2004 Oct; 45(10):14N. PubMed ID: 15551510
    [No Abstract]   [Full Text] [Related]  

  • 3. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 5. Joint Commission expectations related to USP-NF Chapter 797 on compounding sterile preparations.
    Jt Comm Perspect; 2006 Apr; 26(4):5. PubMed ID: 16786622
    [No Abstract]   [Full Text] [Related]  

  • 6. Compounding bevacizumab for intravitreal injection: does USP <797> always apply?
    Shienbaum G; Flynn HW
    Retina; 2013 Oct; 33(9):1733-4. PubMed ID: 23851633
    [No Abstract]   [Full Text] [Related]  

  • 7. Codes + standards. Pharmacy facts. Architectural and environmental changes required for USP 797.
    Bernstein WN
    Health Facil Manage; 2005 Jul; 18(7):39-40. PubMed ID: 16130375
    [No Abstract]   [Full Text] [Related]  

  • 8. Ensuring the safety of identity.
    Masih ST; Martz M; Karam PA;
    Health Phys; 2005 Feb; 88(2 Suppl):S5-8. PubMed ID: 15654246
    [No Abstract]   [Full Text] [Related]  

  • 9. GMPs vs GCPs: United States Pharmacopeia General Chapters.
    Allen LV
    Int J Pharm Compd; 2013; 17(5):439. PubMed ID: 24459791
    [No Abstract]   [Full Text] [Related]  

  • 10. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 11. JCAHO's compliance expectations for standardized concentrations. Rule of Six in pediatrics does not meet requirements.
    Jt Comm Perspect; 2004 May; 24(5):11. PubMed ID: 15224665
    [No Abstract]   [Full Text] [Related]  

  • 12. United States Parmacopeia Chapter <797> timeline: 1989 to 2013.
    Newton DW
    Int J Pharm Compd; 2013; 17(4):283-8. PubMed ID: 24261142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection.
    Hung JC
    J Nucl Med; 2002 Nov; 43(11):1495-506. PubMed ID: 12411554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From molecule to medicine--drug development].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
    [No Abstract]   [Full Text] [Related]  

  • 15. Implementing United States Pharmacopeia Chapter <1163>. Quality assurance in pharmaceutical compounding, Part 3: Testing.
    Allen LV
    Int J Pharm Compd; 2012; 16(4):322-8. PubMed ID: 23050393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Working toward uniformity in evaluation of ADR-reporting programs.
    Woodson HA
    Am J Hosp Pharm; 1991 Jul; 48(7):1428. PubMed ID: 1882866
    [No Abstract]   [Full Text] [Related]  

  • 17. GMPs and GCPs: a topical comparison.
    Allen LV
    Int J Pharm Compd; 2013; 17(1):87. PubMed ID: 23627250
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
    Hyde TD
    Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nuclear medicine entangled by administrative regulations].
    Meyer GJ
    Nuklearmedizin; 2013; 52(2):N11-5. PubMed ID: 23503760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.